Navigation Links
Interleukin-8, key marker for colorectal cancer treatment
Date:10/9/2007

Colorectal cancer (CRC) is currently one of the three most frequent malignancies in Western industrial nations. Although the 5-year survival rate for patients with early stage and local CRC approaches nearly 90%, survival is dramatically decreased by local recurrence and the development of distant metastases that primarily affect the liver, which are the predominant cause of CRC-related mortality.

Although IL-8 expression has been recently correlated with the tumorpathology of various carcinoma types, the role of IL-8 in tumor development and metastasis is still not fully understood and often discussed controversially. Moreover, it remains unclear whether IL-8 expression is related to cancer progression and metastatic potential in colorectal carcinoma tissues.

This issue was addressed by Dr. Rubie and colleagues from the University of the Saarland, Germany. The investigators report on a potential role of IL-8 in the development and metastatic spread of colorectal cancer in the October 7 issue of the World Journal of Gastroenterology.

The article investigates the expression profile of IL-8 in inflammatory (ulcerative colitis), non-malignant (colorectal adenoma) and CRC tissues of different tumor stages as well as in colorectal liver metastases (CRLM) along with their related primary colorectal tumors.

The major findings demonstrate significant IL-8 up-regulation in all inflammatory, non-malignant and malignant colorectal entities compared to their corresponding normal tissues. However, the magnitude of IL-8 expression in surgical CRC tissue specimens correlates with increasing tumor stages and, thus, also with the malignant status of colorectal cancer cells. Moreover, the investigators show for the first time that, irrespective of the tumor stage, IL-8 is significantly higher expressed in CRC tissues compared to inflammatory colorectal conditions and adenomas of the colon/rectum. Since such conditions often constitute prevalent pre-existing disease states in the pathogenesis of colorectal cancer, these results strongly suggest an association between IL-8 up-regulation and the development of CRC. In addition, significant IL-8 overexpression was found in CRLM in comparison to related primary colorectal tumors. Thus, this study not only suggests a correlation between IL-8 expression and the induction and progression of colorectal carcinoma, but also clearly points to a correlation between IL-8 expression and the development of CRLM.

"Monitoring the IL-8 expression level in CRC patients may potentially help to assess the course of cancerous conditions and the prognosis of patients with respect to the development of CRLM. In this respect it is conceivable to monitor the IL-8 expression level in CRC patients that show no diagnosable symptoms of CRLM at the time of presentation, but may still carry a high risk for developing such metastases. A significantly up-regulated level of IL-8 might thus be a useful tool to evaluate the prognosis of patients with CRC with meaningful consequences of treatment. Thus, patients with a higher risk of developing CRLM may receive different treatment compared to patients with a lower risk of developing CRLM."

This study shows that IL-8 may serve as a useful indicator of poor prognosis and a putative target for the development of drugs in CRC therapy.


'/>"/>

Contact: You-De Chang
y.d.chang@wjgnet.com
86-108-538-1901
World Journal of Gastroenterology
Source:Eurekalert

Related biology news :

1. Biomarkers isolated from saliva successfully predict oral and breast cancer
2. UCLA cancer researchers shake loose hidden biomarker
3. Measurement Challenges In Detecting Cancer Biomarkers
4. New markers of climate change
5. U-M scientists discover identifying markers for primitive blood-forming stem cells
6. Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers
7. Biomarkers may hone anti-aging therapies
8. Making a face: A new and earlier marker of neural crest development
9. Major cancer study aims to identify protein markers for early-stage disease
10. Inflammation markers identify fatigue in breast cancer survivors
11. Viral marker of human migration suspect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... Germany , December 15, 2016 ... today announced an agreement with NuData Security, an award-winning ... The partnership will enable clients to focus on good customer ... data protection regulation. ... In order to provide a one-stop fraud prevention ...
(Date:12/15/2016)... DUBLIN , Dec 15, 2016 ... Research and Markets has announced ... to their offering. The report forecasts the global military ... 2016-2020. The report has been prepared based on an ... market landscape and its growth prospects over the coming years. The report ...
(Date:12/15/2016)... 15, 2016  There is much more to innovative ... the engine. Continental will demonstrate the intelligence of today,s ... . Through the combination of the keyless entry ... biometric elements, the international technology company is opening up ... authentication. "The integration of biometric elements brings ...
Breaking Biology News(10 mins):
(Date:1/17/2017)...  Only nine percent of U.S. consumers believe pharmaceutical ... 16 percent believe health insurance companies do, according to ... of U.S. adults believe health care providers (such as ... hospitals (23%). "We are in the midst ... , vice president of reputation management and public affairs ...
(Date:1/17/2017)... ... 2017 , ... Pono Ola , a mind-body wellness firm on a ... official launch of its much-anticipated Pono Board: a re-invented fitness and anti-fatigue balance board ... over a year, the patented Pono Board is the world’s only exercise balance board ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... research, recently announced a collaboration with the Heidelberg University Hospital and the German ... library preparation, following the company’s successful launch of its CATS (Capture and ...
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate Court of ... on the appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. company (DPCL) ... and one of its Dishman Group’s 100% wholly owned New Jersey-based subsidiary Dishman ...
Breaking Biology Technology: